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SUMMARY
The search for antimalarial chemotypes with modes
of action unrelated to existing drugs has intensified
with the recent failure of first-line therapies across
Southeast Asia. Here, we show that the trisubstituted
imidazole MMV030084 potently inhibits hepatocyte
invasion by Plasmodium sporozoites, merozoite
egress from asexual blood stage schizonts, and
male gamete exflagellation. Metabolomic, phospho-
proteomic, and chemoproteomic studies, validated
with conditional knockdown parasites, molecular
docking, and recombinant kinase assays, identified
cGMP-dependent protein kinase (PKG) as the pri-
mary target of MMV030084. PKG is known to play
essential roles in Plasmodium invasion of and egress
from host cells, matching MMV030084’s activity pro-
file. Resistance selections and gene editing identified
tyrosine kinase-like protein 3 as a low-level resis-
tance mediator for PKG inhibitors, while PKG itself
never mutated under pressure. These studies high-
light PKG as a resistance-refractory antimalarial
target throughout the Plasmodium life cycle and
promote MMV030084 as a promising Plasmodium
PKG-targeting chemotype.
INTRODUCTION
Plasmodium falciparum (Pf) malaria, transmitted to humans
through the bites ofAnophelesmosquitoes, kills over 400,000 in-
dividuals each year, mostly young African children (WHO, 2019).
Rapid diagnosis, effective treatment, and vector control have
significantly reduced mortality and morbidity rates since 2000,
but this progress has stalled in recent years. In addition, a major
concern is the emergence and spread in Southeast Asia of Pf
parasites resistant to artemisinins and partner drugs used in ar-
temisinin-based combination therapies (Ross and Fidock, 2019;
van der Pluijm et al., 2019). Consequently, there is an urgent
need to complement the current arsenal of failing antimalarials
with additional chemotypes having novel modes of action.
Human infection begins when Plasmodium sporozoites deliv-
ered during a mosquito bite migrate to the liver to undergo clonal
replication in hepatocytes, generating thousands of merozoites
able to infect red blood cells (RBCs) (Cowman et al., 2016). In
RBCs, parasites develop over ~48 h froma ring into a trophozoite
and eventually a schizont that contains 8-24 merozoites. Upon
lysing their host RBCs, egressed merozoites invade other
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RBCs to perpetuate the asexual blood stage (ABS) cycle that
causes all clinical manifestations ofmalaria. SomeABSparasites
will develop into sexual gametocytes that can continue develop-
ment in mosquitoes after ingestion during a blood meal. In the
mosquito midgut, male and female gametocytes will develop
into gametes, which fuse to form zygotes. These develop into oo-
kinetes and later oocysts, which undergo meiosis and release
thousands of sporozoites ready to infect a human host.
This complex life cycle provides opportunities to develop an-
timalarials with prophylactic (liver stage), curative (ABS), or
transmission-blocking (gametocytes and/or gametes) activity.
Screening platforms using Pf or the rodent-infecting P. berghei
(Pb) species at different developmental stages have identified
thousands of hits with potent activity (Antonova-Koch et al.,
2018; Gamo et al., 2010; Plouffe et al., 2016; Van Voorhis
et al., 2016). However, only rarely are the targets of these hits
known, and even less frequently are compounds found that
show prophylactic, anti-ABS, and transmission-blocking activ-
ity. In addition, it is critical to ensure that antimalarial therapies
have a high barrier to resistance development by the parasite
(Blasco et al., 2017; Phillips et al., 2017).
Here, we report the compound MMV030084, which shows
potent activity against liver, asexual, and sexual blood stage
development. Using chemoproteomic and genetic tools, we
identified and validated cGMP-dependent protein kinase
(PfPKG) as the target. In vitro resistance,mediated by tyrosine ki-
nase-like protein 3 (TKL3), was low-level, making MMV030084 a
promising candidate antimalarial for further development.
RESULTS
MMV030084 Displays Prophylactic, Anti-ABS, and
Transmission-Blocking Antiplasmodial Activity
We first profiled the antiplasmodial life-cycle activity of
MMV030084, a trisubstituted imidazole identified by the Medi-
cines for Malaria Venture (MMV) (Figures 1A and 1B). In liver
stage assays using luciferase-expressing Pb parasites and
host HepG2 liver cells, MMV030084 showed a 50% inhibitory
concentration (IC50) of 199 nM (Figure 1C). This inhibitory activity
peaked during parasite invasion, as indicated by experiments in
which exposure started at different time points (Figure 1C).
Against HepG2 liver cells, MMV030084 showed a 50% cytotoxic
Figure 1. MMV030084 Has Prophylactic, Anti-ABS, and Transmission-Blocking Potential
(A) Structure of MMV030084, a trisubstituted imidazole.
(B) Overall activity profile of MMV030084.
(C) MMV030084 inhibited invasion of P. berghei ANKA parasites into HepG2 liver cells.
(D) Compound dose-response assays with ABS parasite stages, highly synchronized to within 3-h periods of development, indicated that MMV030084 is highly
active only against synchronized schizonts. Minimal activity was observed against rings and trophozoites.
(E) Microscopy studies confirmed that MMV030084 is active against schizonts, showing the profile of an egress inhibitor.
(F) Male gamete formation is inhibited by MMV030084 in the presence of compound, but not when compound is washed out before gamete formation.
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Figure 2. Identification and Validation of PKG as the Primary Target of MMV030084
(A) MMV030084-exposure of schizonts affected the phosphorylation status of several peptides in various pathways and provided evidence indicating that
MMV030084 likely targets a kinase that is central to Pf parasite metabolism.
(B) PKG, CDPK1, and AAT emerged as candidate targets in competitive chemoproteomic studies using bead-bound compounds on treated and untreated
(control) parasite lysates (Table S1 (E1-3)).
(C) Exposing MMV030084-treated parasite lysates to a panel of bead-immobilized kinase inhibitors (Kinobeads) or bead-immobilized MMV030084 (‘084-beads)
identified the lowest Kd
app values for PKG, CDPK1, and AAT. Results shown are the mean of two repeated experiments, except for AAT, which was detected in
only one of the experiments (Table S1 (E1-3)).
(D) cKD of PKG resulted in the largest growth defect compared with control conditions, with cKDs of CDPK1 and AAT affecting parasite growth to a lesser extent.
Error bars indicate the SEM based on two independently repeated experiments with technical duplicates. p values are based on unpaired t tests (Table S1 (F)).
(legend continued on next page)
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concentration (CC50) of 41.5 mM, illustrating low toxicity and high
selectivity for antiplasmodial activity (Figure 1C).
Against Pf ABS parasites, MMV030084 showed an IC50 of
109 nM against the drug-sensitive 3D7-A10 line, and an IC50 of
120 nM against multidrug-resistant Dd2-B2 parasites in a 72-h
growth inhibition assay (Figure 1D). We then explored the timing
of MMV030084 inhibition of 3D7-A10 parasites during ABS
development by exposing synchronized parasites at specific
8-h intervals. MMV030084 activity peaked against schizonts,
with a biphasic survival curve that showed a first shift at
96 nM, a plateau phase at ~58% survival, and a second shift at
3,932 nM (Figure 1D; Table S1 (A)). This biphasic curve suggests
the presence of primary and secondary targets, or some incom-
plete synchronicity in the schizont preparations. MMV030084-
treated rings and trophozoites showed average IC50 values of
5,561 and 3,248 nM, respectively, with monophasic survival
curves. These results were further validated by light microscopy,
showing that ABS development was halted at the schizont stage
when ring-stage parasites were exposed to 350 nM of
MMV030084 (approximately 33 IC50; Figure 1E).
We also tested a panel of MMV030084 analogs (Figure S1A)
from the Tres Cantos Antimalarial Set (Gamo et al., 2010).
MMV030734, included in the MMV Pathogen Box compound li-
brary, showed a 72-h ABS IC50 of 65 nM. Other analogs from this
set showed IC50 values between 86 and 395 nM (Table S1 (B)).
Among these analogs that include known kinase inhibitors,
TCMDC-141334 was earlier reported to be a B-raf kinase inhib-
itor (Gamo et al., 2010).
MMV030084 proved inefficacious against both early and late
stage NF54 gametocytes, showing IC50 values >40 mM in
CBG99-luciferase assays (Siciliano et al., 2017) and saponin
lysis-based sexual stage assays (Plouffe et al., 2008). Nonethe-
less, MMV030084 inhibitedmale gamete exflagellation at an IC50
of 141 nM when gametocytes were stimulated to develop into
male gametes that egress from their host RBCs in the presence
of the compound (Figure 1F). This activity was lost when
MMV030084 was washed out before gamete stimulation,
consistent with the lack of gametocyte killing. Female gamete
formation assay data provided ambiguous results and could
not clearly identify activity of MMV030084 against female gam-
etes (Figure S2).
Exploratory Metabolomics and Phosphoproteomics
Identify a Novel Mode of Action and Implicates the
Kinase-Inhibitory Activity of MMV030084
We first assessed the impact of MMV030084 on the parasite’s
metabolic pathways using an exploratory metabolomics study
on trophozoites and the more MMV030084-susceptibile schiz-
onts. MMV030084 induced only minor changes within the set
of detected metabolites in both stages (Table S1 (C)). This meta-
bolic profile was distinct from inhibitors known to affect targets
such as hemoglobin catabolism, the mitochondrial electron
transport chain, pyrimidine biosynthesis, or cellular homeostasis
(Murithi et al., 2019).
Since the structure of MMV030084 is reminiscent of kinase in-
hibitors, we also analyzed the impact of MMV030084 exposure
(1,200 nM, equivalent to 103 IC50, for 3 h) on the phosphopro-
teome of Dd2-B2 Pf schizonts. Results showed that
MMV030084 exposure reduced the phosphorylation status of
16 proteins by more than 35% compared with untreated control
conditions (Figure 2A; Table S1 (D1,2)). These proteins included
nucleoside transporters 1 and 2, Ras-related protein Rab-1B,
multidrug resistance-associated protein 1, vacuolar proton-trans-
locatingATPase subunit a, erythrocytemembrane-associated an-
tigen, the Pf formate-nitrite transporter, rhomboid-like proteins,
SNF2 helicase, glycogen synthase kinase 3, an RNA-binding pro-
tein, and three uncharacterized proteins including a transporter.
Conversely, 15 proteins showed increased phosphorylation levels
afterMMV030084 treatment comparedwith untreated conditions.
These included a ubiquitin-like domain-containing protein, glideo-
some-associated protein 45, EMP1-trafficking protein, early tran-
scribed membrane protein 5, high molecular weight rhoptry
protein 3, heterochromatin protein 1, eukaryotic translation initia-
tion factor 3 subunit A, innermembrane complex protein 1g, prob-
able cytosolic iron-sulfur protein assembly protein CIAO1 homo-
log, protein dopey homolog, FACT complex subunit SPT16,
cAMP-dependent protein kinase regulatory subunit, polyadeny-
late-binding protein, and two uncharacterized proteins (Figure 2A;
Table S1 (D1,2)). The multitude of proteins and pathways that are
affected suggested thatMMV030084 targets one ormore kinases
central to the parasite’s cellular and developmental regulation.
Chemoproteomics Identify PKG, CDPK1, and AAT as
Putative Targets of MMV030084
We subsequently performed competitive chemoproteomics to
identify binding targets of MMV030084. Our initial approach
involved MMV030084 and its analog TCMDC-141154. The
latter was chosen based on its availability, structural related-
ness, and the presence of a primary amine moiety, which
made it suitable for chemoproteomic profiling as we could atta-
ch this compound to a bead matrix without further modification.
Both compounds were attached to an NHS-activated Sephar-
ose matrix via their primary amine moiety and then incubated
with parasite lysates that had been exposed to either 40 mM
of the same compound or a vehicle control. cGMP-dependent
protein kinase (PKG) (PF3D7_1436600; UniProtKB: Q8I719), a
putative amino acid transporter (AAT) (PF3D7_1231400;
UniProtKB: Q8I5A6), and calcium-dependent protein kinase 1
(CDPK1) (PF3D7_0217500; UniProtKB: P62344) were identified
as the sole three proteins that were pulled down in both the
MMV030084 and TCMDC-141154 competitive chemoproteo-
mic experiments (Figure 2B; Table S1 (E1-3)).
(E) cKD of PKG increased parasite susceptibility toMMV030084, while cKD of CDPK1 or AAT caused no orminor differences inMMV030084 susceptibility versus
control conditions. Results shown are based on four independently repeated experiments with technical duplicates (Table S1 (G)).
(F) MMV030084 and its analogs dock well into the crystal structure of PKG (Table S1 (H)). H-bonding residues are highlighted in the docking graphs.
(G) MMV030084 potently inhibited the kinase activity of recombinant PfPKG in vitro. IC50 data are based on three independently repeated experiments with
technical duplicates. MMV’084, MMV030084; TCMDC‘154, TCMDC-141154; ctrl, control; PKG, cGMP-dependent protein kinase (PF3D7_1436600); CDPK1,
calcium-dependent protein kinase 1 (PF3D7_0217500); AAT, putative amino acid transporter (PF3D7_1231400); Kd
app, apparent dissociation constant; cKD,
conditional knockdown; SEM, standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Our second approach involved parasite lysates being exposed
to different concentrations of MMV030084 and subsequently
incubated with a panel of bead-immobilized, known kinase
inhibitors (Kinobeads assay) or with bead-immobilized
MMV030084. Five independent experiments showed that PKG
and CDPK1 were consistently subject to the highest level of
competition between the beads andMMV030084, with apparent
dissociation constants (Kd
app) below the lowest tested concen-
tration of 0.1 mM (Table S1 (E1-3)). Two follow-up experiments
using lower MMV030084 concentrations yielded more accurate
Kd
app values of 9–16 nM for PKG and 215–220 nM for CDPK1,
highlighting PKG as the primary candidate target of
MMV030084 (Figure 2C; Table S1 (E1-3)). This assay also iden-
tified AAT as a putative binding partner of MMV030084 in one
of the two follow-up experiments, at levels similar to PKG. We
note that AAT was identified from only 2 to 3 peptides from the
same region in the 229-kDa protein, whereas PKGwas identified
by over 30 peptides, suggesting that AAT may be a binding part-
ner of PKG or CDPK1 but not of MMV030084 itself.
The same chemoproteomics approach was also applied to
human mixed tissue extracts to test possible cross-reactivity
of MMV030084 with human proteins. Of the 280 human kinases
that were identified in the assay, seven showed Kd
app values <
100 nM (103 the Kd
app for PKG): receptor interacting serine/thre-
onine kinase 2 (Kd
app = 4.5 nM), protein kinase N3
(Kd
app = 8.5 nM), nemo-like kinase (Kd
app = 20 nM), transforming
growth factor b receptor 1 (Kd
app = 20 nM), testis-associated
actin remodeling kinase 2 (Kd
app = 25 nM), transforming growth
factor b receptor 2 (Kd
app = 35 nM), and casein kinase 1d
(Kd
app = 95 nM) (Table S1 (E1-3)).
Conditional Knockdowns, Molecular Modeling, and
Kinase Inhibition Assays Validate PKG as a Primary
Target for MMV030084’s Antiplasmodial Activity
To further explore PKG, CDPK1, and AAT as candidate targets of
MMV030084, we generated conditional knockdown (cKD) lines
for each of these genes. Using CRISPR/Cas9, Tet repressor pro-
tein aptamers were introduced at the 30 ends of these genes so
that translation could be regulated with anhydrotetracycline
(aTc) (Ganesan et al., 2016; Nasamu et al., 2019). High aTc levels
allow translation, while low aTc levels result in a knockdown of
the gene of interest. cKDs of PKG and CDPK1 were functionally
validated by western blot (Figure S3). We confirmed the
presence of the cKD machinery in the AAT cKD line by Sanger
sequencing, as AAT protein levels were too low in standard con-
ditions to validate by western blot.
We first assessed the essentiality of PKG, CDPK1, and AAT for
Pf ABS by assessing parasite growth in the presence (50 nM) or
absence of aTc. This showed that 97%, 34%, and 25% of para-
site growth was inhibited under PKG, CDPK1, and AAT knock-
down conditions, respectively, compared with controls
(Figure 2D; Table S1 (F)). We then evaluated parasite susceptibil-
ity to MMV030084, and MMV030734 under knockdown versus
wild-type conditions. Dose-response growth inhibition data re-
vealed that parasites were sensitized 4.2-fold to MMV030084
when PKG was knocked down (Figure 2E; Table S1 (G)), consis-
tent with the expected sensitization to a compound when its
target is knocked down (Istvan et al., 2019). The rationale being
that less compound is required to achieve growth inhibition by
binding its target if already there is less functional target in the
parasite. A similar trend, albeit to a lesser degree (1.7-fold
decreased IC50), was observed under AAT cKD conditions. No
change in MMV030084 susceptibility was observed when
CDPK1 was knocked down (Figure 2E). Similar results were ob-
tained for the Pathogen Box analog MMV030734 (Table S1 (G)).
Given that PKG emerged as the primary candidate target for
MMV030084 based on cKD data and that its crystal structure
is available (PDB: 5DYK [Baker et al., 2017]), we modeled
MMV030084 and several of its analogs into the ATP-binding
pocket of PKG. This showed strong docking of MMV030084
and its analogs MMV030734 and TCMDC-141154 in PKG with
scores less than 9.3 and the formation of stable H-bonds
with residues V621, E625, and D682 for all tested compounds
as confirmed by molecular dynamics studies (Figure 2F). Other
MMV030084 analogs also docked well into the crystal structure
of PKG (Table S1 (H)). Kinase inhibition assays using recombi-
nant PfPKG indicated a mean IC50 of 0.4 nM for MMV030084,
indicating potent in vitro inhibition of PKG activity by
MMV030084 (Figure 2G).
To further confirm that CDPK1 is not the primary target of
MMV030084, we tested a previously generated CDPK1 T145M
gatekeeper mutant line, generated in NF54 parasites (Bansal
et al., 2018), for its susceptibility to MMV030084. This gate-
keeper residue mutation reduces accessibility to the small hy-
drophobic pocket adjoining the ATP-binding site that
MMV030084 is predicted to extend into and should, therefore,
reduce sensitivity of CDPK1 to the inhibitor. There was no
change in IC50 to MMV030084 in the CDPK1
T145M line compared
with its parental control (mean IC50 values of 112 nM for the wild-
type NF54 parental line versus 90 nM for the CDPK1T145M
mutant line).
Selection Studies Reveal Lack of Mutation in the PKG
Target and Identify Low-Grade Resistance Mediated
by TKL3
To identify possible resistance mechanisms of MMV030084, we
performed several rounds of in vitroMMV030084 resistance se-
lections (Figure 3A). Continuous exposure of 1 3 109 Dd2-B2
parasites, in triplicate, to 350 nM (33 IC50) of MMV030084
yielded resistant parasites that showed a 2.9-fold IC50 shift
compared with the parental line (Figures 3A and 3B; Table S1
(I)). Whole-genome sequencing of resistant clones obtained by
limited dilution identified a shared T1268R mutation located
outside of the kinase catalytic domain of tyrosine kinase-like pro-
tein 3 or TKL3 (PF3D7_1349300) in all MMV030084-resistant
lines (Figure 3B). To validate this finding, T1268Rwas introduced
into wild-type Dd2-B2 parasites by CRISPR/Cas9 genetic edit-
ing, yielding the edited (ed.) Dd2-B2 TKL3T1268R line. This line
showed a 2.6-fold IC50 shift to MMV030084, similar to the
MMV030084-selected line and validating TKL3 as a
MMV030084-resistance mediator (Figure 3B; Table S1 (I)). The
introduction of the I1250M mutation, a natural variant present
in 3D7, into wild-type Dd2-B2 conferred a similar 2.5-fold IC50
shift, but provided no additional resistance when introduced in
the edited Dd2-B2 TKL3T1268R line. Using the same editing strat-
egy, we also introduced a stop codon and a frameshift at the
T1268 position to produce a truncated TKL3 knockout lacking
the last 539 C-terminal amino acids (termed ed. Dd2-B2
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TKL3KO). This knockout showed a 3.1-fold IC50 shift to
MMV030084, similar to the other edited lines (Figure 3B; Table
S1 (I)).
A TKL3 cKD line, engineered using the same strategy as
mentioned earlier for PKG, showed only a 9% reduction in para-
site growth in the absence of aTc (Figure 3C; Table S1 (F)).
In addition, the TKL3 knockdown induced a 2.1-fold increase
in IC50 to MMV030084 compared with its isogenic control (Fig-
ure 3D; Table S1 (G)). This finding is opposite to the IC50
decrease usually observed for drug targets.
To further assess whether MMV030084 can directly inhibit
TKL3 activity, we used a radioactive in vitro kinase assay with
a recombinant TKL3 construct containing the kinase domain re-
gion. A concentration of 20 mM MMV030084 or other analogs
yielded no reduction in TKL3 kinase activity (Figure S1B). Similar
results were observed for compounds MMV030734, TCMDC-
140762, and TCMDC-141079, indicating that MMV030084 and
other compound analogs did not directly inhibit TKL3 kinase
activity.
We performed additional selections with the edited Dd2-B2
TKL3KO parasites to obtain higher resistance levels and explore
its genetic basis. Continuous exposure of 1 3 109 Dd2-B2
TKL3KO parasites to 1,100 nM of MMV030084 did not result in
parasite recrudescence. A pulsing procedure in which parasites
were exposed to gradually increasing levels of MMV030084
(525–875 nM), however, did result in parasites with an additional
1.5- to 2.2-fold IC50 shift compared with the parental edited Dd2-
B2 TKL3KO line (Figure 3B; Table S1 (I)). These parasites were
cloned and subjected to whole-genome sequencing. This anal-
ysis revealed mutations in either protein phosphatase 1 (PP1)
(PF3D7_1414400) or a putative ubiquitin regulatory protein
(URP) (PF3D7_0808300). H237D and V249L in PP1 were
observed in parasites that displayed an average 1.6-fold shift,
whereas the E20* mutation in URP was associated with a 2.2-
fold IC50 shift to MMV030084 compared with the parental ed.
Dd2-B2 TKL3KO line (Figure 3B; Table S1 (I)).
cKDs of PP1 and URP in TKL3 wild-type parasites resulted in
95% and 12% mean reductions in parasite growth, respectively
(Figures 3C and S3; Table S1 (F)). Neither the PP1 nor the URP
cKD line showed a differential MMV030084 susceptibility
compared with the isogenic controls (Figure 3D; Table S1 (G)),
arguing against these proteins being direct targets of this
compound.
DISCUSSION
Herein, we report the mode of action of and genetic basis of
resistance to MMV030084, a trisubstituted imidazole with potent
Figure 3. Resistance Selections with Cultured Pf ABS Parasites Identify TKL3, PP1, and URP as Low-Level Resistance Mediators for
MMV030084
(A) Outline of the MMV030084 resistance selection attempts that identified TKL3, PP1, and URP as candidate resistance mediators.
(B) Susceptibility of the selected and confirmatory gene-edited clones to MMV030084. Error bars indicate the SEM based onR4 independently repeated ex-
periments with technical duplicates. p values are based on Mann-Whitney U tests (Table S1 (I)).
(C) Parasite growth is only minimally inhibited by cKD of TKL3 and URP, while cKD of PP1 renders ABS parasites effectively non-viable (Table S1 (F)). Error bars
indicate the SEM based on two independently repeated experiments with technical duplicates. p values are based on unpaired t tests.
(D) cKD of TKL3 decreased parasite susceptibility to MMV030084, whereas cKD of PP1 and URP showed no effect. Error bars indicate the SEM based on two
independently repeated experiments with technical duplicates. p values are based on unpaired t tests (Table S1 (G)). Sel., selected; Ed., CRISPR/Cas9 edited;
aTc, anhydrotetracycline; TKL3, tyrosine kinase-like protein 1 (PF3D7_1349300); PP1, protein phosphatase 1 (PF3D7_1414400); URP, ubiquitin regulatory
protein (PF3D7_0808300); cKD, conditional knockdown; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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activity against Pf ABS parasites (Gamo et al., 2010). We further
characterized the activity profile of this compound, which pri-
marily affects schizonts during ABS development, inhibiting
parasite egress from infected RBCs (Figures 1D and 1E). Liver
stage assays revealed potent inhibition of sporozoite host cell in-
vasion without affecting liver trophozoite development (Fig-
ure 1C). MMV030084 also inhibited male gametogenesis
in vitro, but did not kill mature gametocytes directly (Figure 1F).
These results highlight MMV030084 as a valuable antimalarial
candidate with prophylactic, anti-ABS, and transmission-block-
ing properties that fulfill many criteria of the target candidate and
target product profiles for new antimalarials as set forth by MMV
(Burrows et al., 2017).
MMV030084 contains a kinase inhibitor-like hinge binding
motif (Urich et al., 2013). We therefore performed an exploratory
phosphoproteomics analysis that identified a variety of proteins
with a differential phosphorylation status in MMV030084-treated
Dd2-B2 parasites versus DMSO-treated control conditions,
without pinpointing a specific pathway (Figure 2A; Table S1
(D1,2)). Comprehensive target identification and validation
studies, including chemoproteomics, translational cKDs, and
modeling experiments highlighted PKG as the primary target of
MMV030084. PKG showed the lowest Kd
app values in the Kino-
beads assay (Figure 2C), and the largest growth defect and
sensitization to MMV030084 in cKD conditions (Figures 2D and
2E). In addition, MMV030084 docked well into PKG’s ATP-bind-
ing pocket (Figure 2F) and potently inhibited recombinant PKG
activity in vitro (Figure 2G).
We identified PKG consensus motifs in peptides that were
differentially phosphorylated under MMV030084 pressure, and
also in peptides that showed no differences in phosphorylation
status. These studies were performed using the established
PfPKG consensus motif K/RR/KxpS/pT as well as the PfPKA
consensus motif K/RxxpS/pT, based on previous reports of the
extensive overlap in the primary amino acid sequences phos-
phorylated by PKG and PKA (Glass and Krebs, 1979; Francis
et al., 2010). Detailed results revealing phosphorylation motifs
and sites and consensus PKG sites are shown in Table S1 (D1,2).
Chemoproteomic experiments identified CDPK1 and AAT as
putative MMV030084 targets (Figure 2B), yet these displayed
either higher Kd
app values to MMV030084 (Figure 2C) or the
knockdown experiments indicated only a partial growth defect
and a minimal to no IC50 shift to MMV030084 in cKD versus con-
trol conditions for these proteins (Figure 2D). A gatekeeper
mutant (T145M) of CDPK1 showed a similar MMV030084 sus-
ceptibility as its wild-type control, further indicating that
CDPK1 is not the primary target responsible for this compound’s
whole-cell activity. Of interest, CDPK1 is a known cellular target
of PKG (Alam et al., 2015) and the same is thought to be true for
AAT. This may have caused these proteins to bind PKG and
therefore be initially identified as putative targets through che-
moproteomics. CDPK1 could potentially also act as a secondary
target of MMV030084. A major role for CDPK1, however, is not
supported by our cKD data that showed sensitization to
MMV030084 upon reduced expression of PKG, but not of
CDPK1 or AAT, coupled with our finding that the IC50 for
MMV030084 was equivalent against a CDPK1T145M gatekeeper
mutant line (Bansal et al., 2018) compared with its parental con-
trol. A similar small gatekeepermutant, CDPK1T145G, was used in
an earlier study of imidazopyridazine compounds showing that
the Class I category of inhibitors, which were highly potent
against the CDPK1 enzyme, inhibited parasite growth via inhibi-
tion of PKG (Green et al., 2015).
In ABS parasites, PKG is known to play an essential role in regu-
lating egress and invasion (Alam et al., 2015; Taylor et al., 2010).
This kinase regulates the discharge of subtilisin-like serine prote-
ase (SUB1) from secretory organelles, called exonemes, into the
parasitophorous vacuole (Collins et al., 2013). This discharge al-
lows SUB1 to cleave and thereby activate enzymes involved in
parasite egress and invasion. Studies with Pf and P. berghei
show a key role for PKG in helping regulate multiple cellular Ca2+
signals essential for parasite development and transmission (Bro-
chet et al., 2014). This extends to PKG regulation of Ca2+-depen-
dent protein kinase 5, an important egressmediator for ABS para-
sites (Dvorin et al., 2010). These crucial roles of PKG for parasite
egress and invasion are in line with the schizont-specific activity
observed for MMV030084 (Figures 1D and 1E).
PKG also plays an essential role in gametogenesis, regulating
male gamete exflagellation and the rounding up of female game-
tocytes (McRobert et al., 2008). MMV030084 and some of its an-
alogs have previously been identified as inhibitors of female
gamete formation (Miguel-Blanco et al., 2017). In our assays,
MMV030084 potently inhibited male exflagellation (Figure 1F),
but showed ambiguous results regarding female gametocyte
rounding up (Figure S2). At later stages of Pf development in
themosquito, PKGwas also reported to control ookinete motility
(Moon et al., 2009), allowing the parasite to cross the midgut of
the mosquito and establish infection away from digestive en-
zymes in the bloodmeal.
The potent inhibition of hepatocyte invasion by MMV030084
(Figure 1C) is also in agreement with PKG’s role in sporozoite
motility and protein secretion required for invasion (Govindas-
amy et al., 2016). In addition, PKG was also found to regulate
parasite egress from hepatocytes (Falae et al., 2010; Govindas-
amy et al., 2016). However, we were unable to assess this
phenotype for MMV030084 since our assays studied liver stage
development from invasion up until only late liver trophozoites.
Our review of the PKG literature identified structural similarity
between MMV030084 and a trisubstituted pyrrole identified by
Merck (named Compound 1), originally developed for Eimeria
(Gurnett et al., 2002) and later reported to be active against Toxo-
plasma gondii and P. berghei (Diaz et al., 2006). We also
observed a similar set of differentially phosphorylated proteins
in our phosphoproteomic experiments as had been identified us-
ing an imidazopyridine from Merck (named Compound 2) that
also inhibits PKG (Alam et al., 2015). Several of these proteins
are involved in invasion/egress, including the schizont egress an-
tigen-1, Myosin A, glideosome-associated protein 45, and the
membrane skeletal protein IMC-1 (see Table S1 (D1)). We also
observed common proteins identified as contributing to trans-
port (nucleotide transporters 1 and 2), transcriptional regulation
(putative RNA-binding protein), and chromatin regulation (puta-
tive SNF2 helicase). Compounds were also recently identified
in a screen of the GSK Full Diversity Collection against recombi-
nant PKG (Penzo et al., 2019). Of note, our chemoproteomics
studies with MMV030084 ruled out cross-reactivity with other
parasite kinases relevant for antiplasmodial activity (Figures 2B
and 2C). These studies, as well as cKD assays (Figures 2D and
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2E) and CDPK1 gatekeeper mutant studies, consistently pointed
to PKG as the primary target of MMV030084.
To our knowledge, our study is the first to describe resistance
mechanisms selected against a PfPKG inhibitor after drug selec-
tions with cultured Pf ABS parasites. Continuous exposure of
Dd2-B2 parasites to 350 nM (or 33 IC50) MMV030084 resulted
in the T1268R mutation in TKL3, located on a phosphorylation
site outside of its kinase domain. Using CRISPR/Cas9, we vali-
dated this mutation and the natural variant I1250M (present in
3D7 parasites) to confer an approximately 3-fold resistance shift
to MMV030084 compared with parental wild-type Dd2-B2 para-
sites (Figure 3B). TKL3 is a kinase expressed in ABS parasites,
gametocytes and sporozoites. In ABS parasites, it is predomi-
nantly expressed in schizonts and is detected throughout the
cell but does not colocalize with known parasite organelles
(Abdi et al., 2010). In merozoites, TKL3 localizes to elongated
structures with bulbous ends. In immature gametocytes, this
kinase co-localized tomicrotubules, suggesting a role in the sub-
pellicular membrane complex that links cytoskeleton microtu-
bules to the pellicular membrane. This is consistent with TKL3
possessing aMORNmotif that is thought to anchor the cytoskel-
eton to membranous structures in Toxoplasma gondii (Abdi
et al., 2010). Our results suggest that TKL3 is directly involved
in pathways regulating parasite egress from RBCs, as shown
by the ablation of the egress defect in ed. Dd2-B2 TKL3T1268R
compared with wild-type Dd2-B2 parasites. However, TKL3 is
not essential for the parasite as shown by the TKL3 cKD line
showing only a minor growth defect versus isogenic controls
(Figure 3C), and our successful efforts in producing a TKL3
knockout line (Figure 3B). Our data agree with recent genome-
wide P. berghei reverse genetic screens (Gomes et al., 2015).
These findings, however, contrast with earlier targeted single
crossover (Abdi et al., 2010) and double homologous recombi-
nation experiments (Tewari et al., 2010), conducted in Pf and
P. berghei, respectively, which had suggested essentiality or at
least a major fitness defect of TKL3KO lines.
Interestingly,oured.Dd2-B2TKL3KO lineshowedasimilar resis-
tance level to MMV030084 as the ed. Dd2-B2 TKL3T1268R and
TKL3I1250M lines (Figure 3B), suggesting that a 3-fold IC50 shift
may be the maximum resistance level that TKL3 can mediate.
The TKL3 cKD line exhibited decreased susceptibility to
MMV030084 (Figure 3D), in contrast to the increased sensitivity
that is usually observed in cKD lines for drug targets. In addition,
kinase assays using recombinant truncated TKL3 showed no dif-
ference in phosphorylation levels upon exposure to MMV030084
or its analogs compared with control conditions (Figure 3E). A
phosphoproteomics experiment comparing MMV030084-treated
Dd2-B2 TKL3KO parasites with untreated Dd2-B2 TKL3KO para-
sites showedasimilarprofileasobserved inDd2-B2wild-typepar-
asites, with the exception that fewer peptides were observed to
have increased phosphorylation levels in Dd2-B2 TKL3KO (Table
S1 (D1,2)). These data provide evidence that TKL3 is solely a resis-
tancemediatorofMMV030084, andnot its target. It ispossible that
TKL3might activateMMV030084 to increase its potency, and that
mutations or gene deletion leads to reduced drug potency and
thus parasite resistance. A similar scenario was recently demon-
strated with a Pf esterase and the antiplasmodial compound
MMV011438 (Istvan et al., 2017). Alternatively, mutations or gene
deletion in TKL3 might result in differential phosphorylation levels
of one or more essential PKG substrates in the presence of
MMV030084 that chemically inhibits PKG, thus enabling Pf
resistance to this compound. The exact mechanism by which
TKL3 contributes to MMV030084 resistance requires further
experimentation.
We performed additional selections with the ed. Dd2-B2
TKL3KO parasites in order to obtain higher resistance levels
and explore its genetic basis. Single-step selections failed to
yield resistance parasites, but a lengthy pulsing protocol yielded
parasites with a 1.5- to 2.2-fold IC50 shift compared with the
parental ed. Dd2-B2 TKL3KO line. These parasites showed either
H237D or V249L mutations in PP1 or the E20* (stop) mutation in
URP. PP1 and URP cKD lines showed no major changes in sus-
ceptibility to MMV030084, indicating that both are resistance
mediators but not direct targets of MMV030084.
PP1 is considered essential for the parasite’s ABS develop-
ment (Guttery et al., 2014), consistent with our observation of a
large fitness defect under PP1 cKD conditions (Figure 3C). A
recent study on the interactome of PP1 identified multiple inter-
acting partners that are thought to determine PP1’s final localiza-
tion and specificity and make PP1 a central phosphatase regu-
lating several diverse parasite pathways (Hollin et al., 2016).
We could not identify a direct link between PP1 and PKG,
TKL3, or URP. However, PP1 was found to be involved in egress
by regulating the phosphorylation status of Pf skeleton binding
protein 1 (PfSBP1) (Blisnick et al., 2006). PfSBP1 is a transmem-
brane protein located in the parasite’s Maurer’s clefts that regu-
lates the stability of the host cell membrane, thereby facilitating
egress of the parasite from the RBC, with hyperphosphorylation
of PfSBP1 inhibiting egress. The H237D and V249L mutations
could therefore result in a differential interaction of PP1 with its
binding partners to overcome the inhibition of PKG by
MMV030084 and its resulting egress defect.
The link between PKG and URP, however, is less straightfor-
ward. URP likely regulates ubiquitination and degradation of pro-
teins by the proteasome, and it is reported tohavephosphorylation
sites at position S37 and S140 (Collins et al., 2014; Kumar et al.,
2017). A recent report found that PKG phosphorylates RPT1, an
AAA+ATPasepresent in the19Sregulatoryunitof theproteasome,
and regulates parasite proteolysis (Govindasamy et al., 2019).
Interestingly, the same report highlighted the importance of prote-
olysis for invasion by sporozoites of hepatocytes. In line with these
data, the E20* mutation in URP observed in our study might
compensate for an invasion defect induced by PKG inhibition.
Importantly, no mutations in PKG conferring MMV030084
resistance were ever selected in any of our studies. We obtained
only low-level resistance despite extensive efforts to elicit high-
grade resistance. This likely reflects PKG’s critical role in Pf
ABS development. Altogether, our findings highlight PKG as a
validated antimalarial target, and MMV030084 as a promising
antimalarial chemotype active throughout the Pf life cycle.
SIGNIFICANCE
Knowledge of the target of candidate antimalarials is infor-
mative for drug development pipelines aiming to maximize
potency and minimize toxicity. Here, we report the applica-
tion of a multi-pronged target discovery pipeline to identify
the molecular target and mode of action of MMV030084, a
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molecule that we validated to have potential to prevent,
treat, and limit malaria transmission. Results from chemo-
proteomic approaches, validated by gene-editing and con-
ditional knockdown studies, revealed that cGMP-dependent
protein kinase (PKG) is the primary antiplasmodial target.
We also observed potent MMV030084-mediated inhibition
of parasite egress from host red blood cells. This finding
agreeswith the essential role of PKGduring cell-to-cell tran-
sitional stages of the Plasmodium parasite life cycle.
Because resistance development can be a major impedi-
ment for antimalarial efficacy, we also explored how P. fal-
ciparum parasites may become resistant to MMV030084.
Resistance selections showed that the parasite could only
develop low-level resistance, mediated by tyrosine kinase
3 (TKL3). TKL3 is not essential for the parasite, as shown
with our knockout studies, but when mutated allows the
parasite to achieve egress in the presence of MMV030084.
Importantly, PKG itself never mutated during these long-
term selections, highlighting that PKG inhibitors have a rela-
tively low risk for high-grade resistance development, as
compared with many other candidate antimalarials in
development.
This study not only underscores the potential of PKG
inhibitors for malaria control, but also provides an extended
molecular toolbox to validate future analogs that may be
developed.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITY
B Lead Contact
B Materials Availability
B Data and Code Availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
d METHOD DETAILS
B Liver Stage Susceptibility Testing
B Asexual Blood Stage Susceptibility Testing
B Gametocyte Susceptibility
B Dual Gamete Formation Assay
B Metabolomics
B Phosphoproteomics
B Chemoproteomics
B Generation of Constructs and Parasite Transfections
for cKD Lines
B Verification of Conditional Knockdown (cKD) Strategy
B Growth Assays Using cKD Lines
B Compound Susceptibility Assays Using cKD Lines
B PfPKG Docking Studies
B Recombinant PfPKG Inhibition Assay
B Selections for MMV030084 Resistance
B Whole-Genome Sequencing
B CRISPR/Cas9 Editing of TKL3
B Expression, Purification and Kinase Assay of WT and
Kinase Dead Recombinant PfTKL3 Kinase Domain
d QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
chembiol.2020.04.001.
ACKNOWLEDGMENTS
This work was supported by the Bill and Melinda Gates Foundation that
funds the Malarial Drug Accelerator (MalDA) consortium (OPP1054480 to
E.A.W., D.A.F., M.C.S.L., and M.L., and OPP1162467 to J.C.N.), the Medi-
cines for Malaria Venture (08/0015 to D.A.F.), the NIH (R01 AI090141 to
E.A.W.) the Italian Ministries of Health and Foreign Affairs (ISARP2018-ISS
to P.A.), and the LSHTM/Wellcome ISSF (to M.D.). K.C. gratefully acknowl-
edges the support of the University of Cape Town, the South African Medical
Research Council, the South African Research Chairs Initiative of
the Department of Science and Innovation administered through the South
African National Research Foundation, and the Global Challenges Research
Fund (Synchrotron Techniques for African Research and Technology proj-
ect). S.M. was supported by a Human Frontier Science Program long-term
fellowship award. We sincerely thank the team at Cellzome for the chemo-
proteomic experiments, Drs. Louis Miller and Karthigayan Gunalan at the
NIH for providing the CDPK1T145M NF54 mutant line, and Dr. David Baker
at the London School of Hygiene & Tropical Medicine, UK for providing
the PfPKG expression construct. MMV030084 (TCMDC-140369) and
MMV030734 (TCMDC-141019) were kindly provided by MMV, and the other
TCMDC analogs (Figure S1A) were kindly provided by GlaxoSmithKline, Tres
Cantos, Spain, through the MalDA consortium.
AUTHOR CONTRIBUTIONS
M.V. and J.M.M. performed ABS specificity assays and exposure studies.
N.M., S.O., and E.A.W. performed liver stage assays. G.S., P.A., S.O., and
E.A.W. assessed gametocytocidal activity of compounds. M.D. performed
the dual gamete formation assay. E.S.O. and M.L. performed metabolomics
experiments. L.D. and A.B.T. performed phosphoproteomic studies. S.G.-D.
supervised the chemoproteomic studies that were performed at Cellzome
with help from S.O. and B.M. C.F.A.P. and J.C.N. generated and phenotyped
the cKD lines. K.J.W. performed PKG docking studies. L.B.A. and K.C. per-
formed recombinant PfPKG kinase inhibition studies. M.V., J.M.M., and
K.T.S. performed resistance selections. T.Y., S.M., M.J.G., and A.-C.U. per-
formed whole-genome sequencing of these lines. M.C.S.L. and E.F.C. de-
signed and produced CRISPR-Cas9 plasmids. M.V., J.M.M., N.S., and
E.F.C. performed CRISPR-Cas9 editing experiments to validate resistance
mediators. M.B. and C.D. performed recombinant TKL3 studies. M.V.
compiled all the data and wrote the manuscript with J.M.M. and D.A.F., with
input from other authors. All authors approved the final manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: February 15, 2020
Revised: March 20, 2020
Accepted: March 31, 2020
Published: April 30, 2020
REFERENCES
Abdi, A., Eschenlauer, S., Reininger, L., and Doerig, C. (2010). SAM domain-
dependent activity of PfTKL3, an essential tyrosine kinase-like kinase of the
human malaria parasite Plasmodium falciparum. Cell Mol. Life Sci. 67,
3355–3369.
Agrawal, S., Kumar, S., Sehgal, R., George, S., Gupta, R., Poddar, S., Jha, A.,
and Pathak, S. (2019). El-MAVEN: a fast, robust, and user-friendly mass spec-
trometry data processing engine for metabolomics. Methods Mol. Biol. 1978,
301–321.
Alam, M.M., Solyakov, L., Bottrill, A.R., Flueck, C., Siddiqui, F.A., Singh, S.,
Mistry, S., Viskaduraki, M., Lee, K., Hopp, C.S., et al. (2015).
Cell Chemical Biology 27, 1–11, June 18, 2020 9
Please cite this article in press as: Vanaerschot et al., Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage,
and Transmission-Blocking Antiplasmodial Activity, Cell Chemical Biology (2020), https://doi.org/10.1016/j.chembiol.2020.04.001
Phosphoproteomics reveals malaria parasite protein kinase G as a signalling
hub regulating egress and invasion. Nat. Commun. 6, 7285.
Allman, E.L., Painter, H.J., Samra, J., Carrasquilla, M., and Llinas, M. (2016).
Metabolomic profiling of the malaria box reveals antimalarial target pathways.
Antimicrob. Agents Chemother. 60, 6635–6649.
Antonova-Koch, Y., Meister, S., Abraham, M., Luth, M.R., Ottilie, S., Lukens,
A.K., Sakata-Kato, T., Vanaerschot, M., Owen, E., Jado, J.C., et al. (2018).
Open-source discovery of chemical leads for next-generation chemoprotec-
tive antimalarials. Science 362, aat9446.
Baker, D.A., Stewart, L.B., Large, J.M., Bowyer, P.W., Ansell, K.H., Jimenez-
Diaz, M.B., El Bakkouri, M., Birchall, K., Dechering, K.J., Bouloc, N.S., et al.
(2017). A potent series targeting the malarial cGMP-dependent protein kinase
clears infection and blocks transmission. Nat. Commun. 8, 430.
Bansal, A., Molina-Cruz, A., Brzostowski, J., Liu, P., Luo, Y., Gunalan, K., Li, Y.,
Ribeiro, J.M.C., and Miller, L.H. (2018). PfCDPK1 is critical for malaria parasite
gametogenesis and mosquito infection. Proc. Natl. Acad. Sci. U S A 115,
774–779.
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson,
S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007). Quantitative
chemical proteomics reveals mechanisms of action of clinical ABL kinase in-
hibitors. Nat. Biotechnol. 25, 1035–1044.
Bantscheff, M., Hopf, C., Savitski, M.M., Dittmann, A., Grandi, P., Michon,
A.M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011).
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of
HDAC complexes. Nat. Biotechnol. 29, 255–265.
Blasco, B., Leroy, D., and Fidock, D.A. (2017). Antimalarial drug resistance:
linking Plasmodium falciparum parasite biology to the clinic. Nat. Med. 23,
917–928.
Blisnick, T., Vincensini, L., Fall, G., and Braun-Breton, C. (2006). Protein phos-
phatase 1, a Plasmodium falciparum essential enzyme, is exported to the host
cell and implicated in the release of infectious merozoites. Cell Microbiol. 8,
591–601.
Brochet, M., Collins, M.O., Smith, T.K., Thompson, E., Sebastian, S.,
Volkmann, K., Schwach, F., Chappell, L., Gomes, A.R., Berriman, M., et al.
(2014). Phosphoinositide metabolism links cGMP-dependent protein kinase
G to essential Ca(2)(+) signals at key decision points in the life cycle of malaria
parasites. PLoS Biol. 12, e1001806.
Burrows, J.N., Duparc, S., Gutteridge, W.E., Hooft van Huijsduijnen, R.,
Kaszubska, W., Macintyre, F., Mazzuri, S., Mohrle, J.J., and Wells, T.N.C.
(2017). New developments in anti-malarial target candidate and product pro-
files. Malar. J. 16, 26.
Cevenini, L., Camarda, G., Michelini, E., Siciliano, G., Calabretta, M.M., Bona,
R., Kumar, T.R., Cara, A., Branchini, B.R., Fidock, D.A., et al. (2014). Multicolor
bioluminescence boosts malaria research: quantitative dual-color assay and
single-cell imaging in Plasmodium falciparum parasites. Anal. Chem. 86,
8814–8821.
Collins, C.R., Hackett, F., Strath, M., Penzo, M., Withers-Martinez, C., Baker,
D.A., and Blackman, M.J. (2013). Malaria parasite cGMP-dependent protein
kinase regulates blood stage merozoite secretory organelle discharge and
egress. PLoS Pathog. 9, e1003344.
Collins, M.O., Wright, J.C., Jones, M., Rayner, J.C., and Choudhary, J.S.
(2014). Confident and sensitive phosphoproteomics using combinations of
collision induced dissociation and electron transfer dissociation.
J. Proteomics 103, 1–14.
Cowman, A.F., Healer, J., Marapana, D., andMarsh, K. (2016). Malaria: biology
and disease. Cell 167, 610–624.
Deitsch, K., Driskill, C., and Wellems, T. (2001). Transformation of malaria par-
asites by the spontaneous uptake and expression of DNA from human eryth-
rocytes. Nucleic Acids Res. 29, 850–853.
Delves, M.J., Straschil, U., Ruecker, A., Miguel-Blanco, C., Marques, S.,
Dufour, A.C., Baum, J., and Sinden, R.E. (2016). Routine in vitro culture of
P. falciparum gametocytes to evaluate novel transmission-blocking interven-
tions. Nat. Protoc. 11, 1668–1680.
Diaz, C.A., Allocco, J., Powles, M.A., Yeung, L., Donald, R.G., Anderson, J.W.,
and Liberator, P.A. (2006). Characterization of Plasmodium falciparum cGMP-
dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor.
Mol. Biochem. Parasitol. 146, 78–88.
Dvorin, J.D., Martyn, D.C., Patel, S.D., Grimley, J.S., Collins, C.R., Hopp, C.S.,
Bright, A.T., Westenberger, S., Winzeler, E., Blackman, M.J., et al. (2010). A
plant-like kinase in Plasmodium falciparum regulates parasite egress from
erythrocytes. Science 328, 910–912.
Falae, A., Combe, A., Amaladoss, A., Carvalho, T., Menard, R., and Bhanot, P.
(2010). Role of Plasmodium berghei cGMP-dependent protein kinase in late
liver stage development. J. Biol. Chem. 285, 3282–3288.
Francis, S.H., Busch, J.L., Corbin, J.D., and Sibley, D. (2010). cGMP-depen-
dent protein kinases and cGMP phosphodiesterases in nitric oxide and
cGMP action. Pharmacol. Rev. 62, 525–563.
Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz,
D.T., Repasky, M.P., Knoll, E.H., Shelley, M., Perry, J.K., et al. (2004). Glide:
a new approach for rapid, accurate docking and scoring. 1. Method and
assessment of docking accuracy. J. Med. Chem. 47, 1739–1749.
Gamo, F.J., Sanz, L.M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.L.,
Vanderwall, D.E., Green, D.V., Kumar, V., Hasan, S., et al. (2010). Thousands
of chemical starting points for antimalarial lead identification. Nature 465,
305–310.
Ganesan, S.M., Falla, A., Goldfless, S.J., Nasamu, A.S., and Niles, J.C. (2016).
Synthetic RNA-protein modules integrated with native translationmechanisms
to control gene expression in malaria parasites. Nat. Commun. 7, 10727.
Glass, D.B., and Krebs, E.G. (1979). Comparison of the substrate specificity of
adenosine 3’:5’-monophosphate- and guanosine 3’:5’-monophosphate-
dependent protein kinases. Kinetic studies using synthetic peptides corre-
sponding to phosphorylation sites in histone H2B. J. Biol. Chem. 254,
9728–9738.
Gomes, A.R., Bushell, E., Schwach, F., Girling, G., Anar, B., Quail, M.A., Herd,
C., Pfander, C., Modrzynska, K., Rayner, J.C., et al. (2015). A genome-scale
vector resource enables high-throughput reverse genetic screening in a ma-
laria parasite. Cell Host Microbe 17, 404–413.
Govindasamy, K., Jebiwott, S., Jaijyan, D.K., Davidow, A., Ojo, K.K., Van
Voorhis, W.C., Brochet, M., Billker, O., and Bhanot, P. (2016). Invasion of he-
patocytes by Plasmodium sporozoites requires cGMP-dependent protein ki-
nase and calcium dependent protein kinase 4. Mol. Microbiol. 102, 349–363.
Govindasamy, K., Khan, R., Snyder, M., Lou, H.J., Du, P., Kudyba, H.M.,
Muralidharan, V., Turk, B.E., andBhanot, P. (2019).Plasmodium falciparum cy-
clic GMP-dependent protein kinase interacts with a subunit of the parasite
proteasome. Infect. Immunol. 87, 00518–00523.
Green, J.L., Moon, R.W., Whalley, D., Bowyer, P.W., Wallace, C., Rochani, A.,
Nageshan, R.K., Howell, S.A., Grainger, M., Jones, H.M., et al. (2015).
Imidazopyridazine inhibitors of Plasmodium falciparum calcium-dependent
protein kinase 1 also target cyclic GMP-dependent protein kinase and heat
shock protein 90 to kill the parasite at different stages of intracellular develop-
ment. Antimicrob. Agents Chemother. 60, 1464–1475.
Gurnett, A.M., Liberator, P.A., Dulski, P.M., Salowe, S.P., Donald, R.G.,
Anderson, J.W., Wiltsie, J., Diaz, C.A., Harris, G., Chang, B., et al. (2002).
Purification and molecular characterization of cGMP-dependent protein ki-
nase from Apicomplexan parasites. A novel chemotherapeutic target.
J. Biol. Chem. 277, 15913–15922.
Guttery, D.S., Poulin, B., Ramaprasad, A., Wall, R.J., Ferguson, D.J., Brady,
D., Patzewitz, E.M., Whipple, S., Straschil, U., Wright, M.H., et al. (2014).
Genome-wide functional analysis of Plasmodium protein phosphatases re-
veals key regulators of parasite development and differentiation. Cell Host
Microbe 16, 128–140.
Hollin, T., De Witte, C., Lenne, A., Pierrot, C., and Khalife, J. (2016). Analysis of
the interactome of the Ser/Thr protein phosphatase type 1 in Plasmodium fal-
ciparum. BMC Genomics 17, 246.
Hughes, C.S., Foehr, S., Garfield, D.A., Furlong, E.E., Steinmetz, L.M., and
Krijgsveld, J. (2014). Ultrasensitive proteome analysis using paramagnetic
bead technology. Mol. Syst. Biol. 10, 757.
10 Cell Chemical Biology 27, 1–11, June 18, 2020
Please cite this article in press as: Vanaerschot et al., Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage,
and Transmission-Blocking Antiplasmodial Activity, Cell Chemical Biology (2020), https://doi.org/10.1016/j.chembiol.2020.04.001
Istvan, E.S., Das, S., Bhatnagar, S., Beck, J.R., Owen, E., Llinas, M., Ganesan,
S.M., Niles, J.C., Winzeler, E., Vaidya, A.B., et al. (2019). Plasmodium
Niemann-Pick type C1-related protein is a druggable target required for para-
site membrane homeostasis. eLife 8, 40529.
Istvan, E.S., Mallari, J.P., Corey, V.C., Dharia, N.V., Marshall, G.R., Winzeler,
E.A., and Goldberg, D.E. (2017). Esterase mutation is a mechanism of resis-
tance to antimalarial compounds. Nat. Commun. 8, 14240.
Kumar, S., Kumar, M., Ekka, R., Dvorin, J.D., Paul, A.S., Madugundu, A.K.,
Gilberger, T., Gowda, H., Duraisingh, M.T., Keshava Prasad, T.S., et al.
(2017). PfCDPK1 mediated signaling in erythrocytic stages of Plasmodium fal-
ciparum. Nat. Commun. 8, 63.
McRobert, L., Taylor, C.J., Deng, W., Fivelman, Q.L., Cummings, R.M., Polley,
S.D., Billker, O., and Baker, D.A. (2008). Gametogenesis in malaria parasites is
mediated by the cGMP-dependent protein kinase. PLoS Biol. 6, e139.
Miguel-Blanco, C., Molina, I., Bardera, A.I., Diaz, B., de Las Heras, L., Lozano,
S., Gonzalez, C., Rodrigues, J., Delves, M.J., Ruecker, A., et al. (2017).
Hundreds of dual-stage antimalarial molecules discovered by a functional
gametocyte screen. Nat. Commun. 8, 15160.
Moon, R.W., Taylor, C.J., Bex, C., Schepers, R., Goulding, D., Janse, C.J.,
Waters, A.P., Baker, D.A., and Billker, O. (2009). A cyclic GMP signalling mod-
ule that regulates gliding motility in a malaria parasite. PLoS Pathog. 5,
e1000599.
Murithi, J.M., Owen, E.S., Istvan, E.S., Lee, M.C.S., Ottilie, S., Chibale, K.,
Goldberg, D.E., Winzeler, E.A., Llinas, M., Fidock, D.A., et al. (2019).
Combining stage specificity andmetabolomic profiling to advance antimalarial
drug discovery. Cell Chem. Biol. 27, 158–171.
Nasamu, A.S., Falla, A., Pasaje, C.F.A., Wall, B.A., Wagner, J.C., Ganesan,
S.M., Goldfless, S.J., and Niles, J.C. (2019). An integrated platform for genome
engineering and gene expression perturbation in Plasmodium falciparum.
bioRxiv. https://doi.org/10.1101/816504.
Paquet, T., Le Manach, C., Cabrera, D.G., Younis, Y., Henrich, P.P., Abraham,
T.S., Lee, M.C.S., Basak, R., Ghidelli-Disse, S., Lafuente-Monasterio, M.J.,
et al. (2017). Antimalarial efficacy of MMV390048, an inhibitor of
Plasmodium phosphatidylinositol 4-kinase. Sci. Transl. Med. 9, aad9735.
Penzo, M., de Las Heras-Duena, L., Mata-Cantero, L., Diaz-Hernandez, B.,
Vazquez-Muniz, M.J., Ghidelli-Disse, S., Drewes, G., Fernandez-Alvaro, E.,
and Baker, D.A. (2019). High-throughput screening of the Plasmodium falcip-
arum cGMP-dependent protein kinase identified a thiazole scaffold which kills
erythrocytic and sexual stage parasites. Sci. Rep. 9, 7005.
Phillips, M.A., Burrows, J.N., Manyando, C., van Huijsduijnen, R.H., Van
Voorhis, W.C., and Wells, T.N.C. (2017). Malaria. Nat. Rev. Dis. Primers
3, 17050.
Plouffe, D., Brinker, A., McNamara, C., Henson, K., Kato, N., Kuhen, K., Nagle,
A., Adrian, F., Matzen, J.T., Anderson, P., et al. (2008). In silico activity profiling
reveals the mechanism of action of antimalarials discovered in a high-
throughput screen. Proc. Natl. Acad. Sci. U S A 105, 9059–9064.
Plouffe, D.M.,Wree,M., Du, A.Y., Meister, S., Li, F., Patra, K., Lubar, A., Okitsu,
S.L., Flannery, E.L., Kato, N., et al. (2016). High-throughput assay and discov-
ery of small molecules that interrupt malaria transmission. Cell Host Microbe
19, 114–126.
Ross, L.S., and Fidock, D.A. (2019). Elucidating mechanisms of drug-resistant
Plasmodium falciparum. Cell Host Microbe 26, 35–47.
Ruecker, A., Mathias, D.K., Straschil, U., Churcher, T.S., Dinglasan, R.R.,
Leroy, D., Sinden, R.E., and Delves, M.J. (2014). A male and female gameto-
cyte functional viability assay to identify biologically relevant malaria transmis-
sion-blocking drugs. Antimicrob. Agents Chemother. 58, 7292–7302.
Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R., and Sherman, W.
(2013). Protein and ligand preparation: parameters, protocols, and influence
on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221–234.
Siciliano, G., Santha Kumar, T.R., Bona, R., Camarda, G., Calabretta, M.M.,
Cevenini, L., Davioud-Charvet, E., Becker, K., Cara, A., Fidock, D.A., et al.
(2017). A high susceptibility to redox imbalance of the transmissible stages
of Plasmodium falciparum revealed with a luciferase-based mature gameto-
cyte assay. Mol. Microbiol. 104, 306–318.
Sridharan, S., Kurzawa, N., Werner, T., Gunthner, I., Helm, D., Huber, W.,
Bantscheff, M., and Savitski, M.M. (2019). Proteome-wide solubility and ther-
mal stability profiling reveals distinct regulatory roles for ATP. Nat. Commun.
10, 1155.
Taylor, H.M., McRobert, L., Grainger, M., Sicard, A., Dluzewski, A.R., Hopp,
C.S., Holder, A.A., and Baker, D.A. (2010). The malaria parasite cyclic GMP-
dependent protein kinase plays a central role in blood-stage schizogony.
Eukaryot. Cell 9, 37–45.
Tewari, R., Straschil, U., Bateman, A., Bohme, U., Cherevach, I., Gong, P.,
Pain, A., and Billker, O. (2010). The systematic functional analysis of
Plasmodium protein kinases identifies essential regulators of mosquito trans-
mission. Cell Host Microbe 8, 377–387.
Urich, R., Wishart, G., Kiczun, M., Richters, A., Tidten-Luksch, N., Rauh, D.,
Sherborne, B., Wyatt, P.G., and Brenk, R. (2013). De novo design of protein ki-
nase inhibitors by in silico identification of hinge region-binding fragments.
ACS Chem. Biol. 8, 1044–1052.
van der Pluijm, R.W., Imwong, M., Chau, N.H., Hoa, N.T., Thuy-Nhien, N.T.,
Thanh, N.V., Jittamala, P., Hanboonkunupakarn, B., Chutasmit, K., Saelow,
C., et al. (2019). Determinants of dihydroartemisinin-piperaquine treatment
failure in Plasmodium falciparum malaria in Cambodia, Thailand, and
Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet
Infect. Dis. 19, 952–961.
Van Voorhis, W.C., Adams, J.H., Adelfio, R., Ahyong, V., Akabas, M.H., Alano,
P., Alday, A., Aleman Resto, Y., Alsibaee, A., Alzualde, A., et al. (2016). Open
source drug discovery with themalaria box compound collection for neglected
diseases and beyond. PLoS Pathog. 12, e1005763.
Werner, T., Sweetman, G., Savitski, M.F., Mathieson, T., Bantscheff, M., and
Savitski, M.M. (2014). Ion coalescence of neutron encoded TMT 10-plex re-
porter ions. Anal. Chem. 86, 3594–3601.
WHO. (2019). World Malaria Report 2019 (World Health Organization). https://
www.who.int/publications-detail/world-malaria-report-2019.
Cell Chemical Biology 27, 1–11, June 18, 2020 11
Please cite this article in press as: Vanaerschot et al., Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage,
and Transmission-Blocking Antiplasmodial Activity, Cell Chemical Biology (2020), https://doi.org/10.1016/j.chembiol.2020.04.001
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Cy3-conjugated anti-Pfs25 antibody (Ruecker et al., 2014) N/A
Mouse anti-HA antibody Sigma-Aldrich Cat# H3663; RRID: AB_262051
Rabbit anti-GAPDH antibody Abcam Cat# ab9485; RRID: AB_307275
Anti-mouse antibody Thermo Fisher Scientific Cat# 62-6520; RRID: AB_2533947
Anti-rabbit antibody Cell Signaling Technology Cat# 7074S; RRID: AB_2099233
Bacterial and Virus Strains
Escherichia coli Rosetta2-pLysS cells EMD Millipore https://www.emdmillipore.com/
Biological Samples
HEK-293 human embryonic kidney
cell line
ATCC https://www.atcc.org
K-562 human bone marrow cell line ATCC https://www.atcc.org
Hep G2 human hepatocellular
carcinoma cell line
ATCC https://www.atcc.org
Placenta (tissue protein extract) ATCC https://www.atcc.org
Chemicals, Peptides, and Recombinant Proteins
All tested antimalarials and their
structures are available in Figure S1.
N/A
MMV030084 (TCMDC-140369) Medicines for Malaria Venture, Geneva,
Switzerland
N/A
TCMDC-140680 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-141334 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-141060 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-141070 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-140700 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-140762 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-140549 GlaxoSmithKline, Tres Cantos, Spain N/A
TCMDC-141154 GlaxoSmithKline, Tres Cantos, Spain N/A
MMV030734 (TCMDC-141019) Medicines for Malaria Venture, Geneva,
Switzerland
N/A
BrightGlo reagent Promega https://www.promega.com/
MitoTracker Deep Red Thermo Scientific https://www.thermofisher.com/
D-Luciferin PerkinElmer https://www.perkinelmer.com/
TMTsixplex reagents Thermo Scientific https://www.thermofisher.com/
AKTA purifier GE Healthcare https://www.gehealthcare.com/
NHS-activated Sepharose matrix Sigma-Aldrich https://www.sigmaaldrich.com/
Mini-PROTEAN TGX Precast Gels Bio-Rad https://www.bio-rad.com/
SuperSignal West Pico
Chemiluminescent substrate
Thermo Fisher Scientific Cat# PI34080
anhydrotetracycline Sigma-Aldrich Cat# 37919
ML10 LifeArc https://www.lifearc.org/
WR99210 Sigma-Aldrich https://www.sigmaaldrich.com/
Critical Commercial Assays
ADP-Glo Kinase Kit Promega https://www.promega.com/
Nextera XT kit Illumina https://www.illumina.com/
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David
Fidock (df2260@cumc.columbia.edu).
Materials Availability
Please note that availability of experimental compounds may be restricted and might require resynthesis. Chemical structures for
MMV030084 and select analogs from the Tres Cantos Antimalarial Set are shown in Figure S1A.
Data and Code Availability
All datasets generated during this study are provided in separate spreadsheets as part of Table S1.
No code was generated.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Peptide substrate GRTGRRNSI-NH2 Sigma-Aldrich Cat# SCP0212
Renilla-Glo(R) Luciferase Assay System Promega Cat# E2750
QiAmp DNA Blood Mini kit Qiagen https://www.qiagen.com/
Deposited Data
PKG crystal structure (Baker et al., 2017) PDB ID: 5DYK
Experimental Models: Organisms/Strains
Anopheles stephensi mosquitoes Insectary Core
Facility, New York University
N/A
Plasmodium falciparum asexual blood
stage parasites
Goldberg lab, Washington University 3D7-A10 clone
P. falciparum asexual blood stage
parasites
Fidock lab, Columbia UniversityMedical
Center
Dd2-B2 clone
P. falciparum NF54 CDPK1 T145M line Miller lab, Malaria Cell Biology, NIAID,
NIH (Bansal et al., 2018)
CDPK1T145M
P. falciparum 3D7elo1-pfs16-CBG99
transgenic parasites
Fidock lab, Columbia UniversityMedical
Center (Cevenini et al., 2014)
N/A
BALB/c female mice The Jackson Laboratory https://www.jax.org/
P. berghei ANKA (Pb-Luc) Insectary Core
Facility, New York University
Pb-Luc, also known as P. berghei-
ANKA-GFP-Luc-SMCON
Oligonucleotides
All primers and cloning fragments are
shown in Table S1 (J) and (K)
N/A
Recombinant DNA
pSN054 vector (Nasamu et al., 2019) N/A
pET28-PfTKL3-SAM(V54E)-KD (Abdi et al., 2010) N/A
Software and Algorithms
GraphPad Prism Version 8 GraphPad Software, San Diego,
CA, USA
www.graphpad.com
ICY BioImage Analysis (Delves et al., 2016) http://icy.bioimageanalysis.org/
R Studio RStudio Team, 2015 http://www.rstudio.com/
Proteome Discoverer Thermo Scientific https://www.thermofisher.com/us/en/
home.html
Mascot Matrix Science http://www.matrixscience.com/
Scaffold Q+S Proteome Software http://www.proteomesoftware.com/
ChemiDoc MP System and
Image Lab 5.2.0
Bio-Rad https://www.bio-rad.com/
El- MAVEN software (Agrawal et al., 2019) https://elucidatainc.github.io/ElMaven/
Schrodinger molecular modeling suite Schrodinger http://www.schrodinger.com/
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
The Pf parasites used in this study were cultured in human O+ blood (sex of donor unknown) at 3% hematocrit in RPMI-1640 media
supplementedwith 50 mMhypoxanthine, 2 g L-1 sodiumbicarbonate, 2mML-glutamine, 25mMHEPES, 0.5%AlbuMAXII (Invitrogen)
and 10 mg mL-1 gentamycin in 5% O2, 5% CO2 and 90% N2 at 37
C. The Dd2-B2 Pf line was cloned by limiting dilution from Dd2 (a
kind gift from Thomas Wellems, NIAID, NIH, Rockville, MD). The 3D7-A10 Pf clone was provided by Dan Goldberg (Washington Uni-
versity, St. Louis, MO). The NF54 and CDPK1 conditional knockdown lines were provided by Louis Miller (NIAID, NIH, Rockville, MD)
(Bansal et al., 2018). Routine sequencing of the drug resistance markers pfcrt, dhfr and K13, accompanied by whole-genome
sequencing of parental lines, was used to authenticate cell lines.
METHOD DETAILS
Liver Stage Susceptibility Testing
P. berghei ANKA infections were maintained in BALB/c female mice (The Jackson Laboratory) infected via intraperitoneal injection of
23107 blood stage parasites. Infected mice were provided water ad libitum and housed in standard cages in an animal facility room
maintained at 22C and 50-70% relative humidity. Anopheles stephensimosquitoes were housed in an insectary maintained at 27C,
80% humidity and a 12:12 light:dark schedule. The timing of MMV030084 activity against P. berghei liver stages was determined
using a luciferase-based assay (Antonova-Koch et al., 2018). 24 h before infection, 384-well plates (Greiner Bio) were seeded with
1x104 HepG2-A16-CD81EGFP cells in 30 mL of assay medium (DMEM without Phenol Red (Life Technologies, CA), 5% FBS and
5x Pen-Strep Glutamine (Life Technologies, CA)). Luciferase-expressing Pb (PbLuc) sporozoites were freshly obtained by dissecting
salivary glands of infected Anopheles stephensi mosquitoes and 5x103 sporozoites in 30 mL were added to each well. Plates were
centrifuged for 5 min at 330g and incubated for 2 h at 37C and 5%CO2. Unbound sporozoites were then removed by centrifugation
and washing and 30 mL of fresh medium was added. 12-point serial dilutions of test and control compounds in DMSOwere added to
the wells either 4 h before or 2 h after infection (corresponding to pre-infection and post-infection treatments, respectively). At 48 h
post-infection, medium was removed and 20 mL of BrightGlo reagent (Promega) was added to each well. Luminescence was
measured using an Envision Multilabel Reader (PerkinElmer) to assess parasite growth as a function of compound concentrations.
Asexual Blood Stage Susceptibility Testing
Unsynchronized parasites were exposed for 72 h to 10 different concentrations of MMV030084 or its analogs, plus control no-drug
conditions, starting with predominantly rings (Murithi et al., 2019). We also exposed specific stages of highly-synchronized parasites
to MMV030084 to determine the period of peak activity, defined as the asexual blood stage at which the compounds showed the
lowest IC50
8h values (Murithi et al., 2019). Synchronicity was achieved using three rounds of sorbitol treatment on early rings, spaced
48 h apart, followed bymagnetic purification of segmented schizonts following the final sorbitol treatment. Parasites were highly syn-
chronous to within a 3 h window of development. Assays were repeated on at least three independent occasions (each with technical
duplicates) and statistical significance was assessed using Mann Whitney U tests.
Gametocyte Susceptibility
This was determined using two separate assays. The first involved MitoTracker staining and high-content imaging. Mature (stage V)
gametocytes were generated from NF54 ABS cultures as described elsewhere (Plouffe et al., 2016). Briefly, asexual parasites were
cultured at 5% hematocrit in O+ human erythrocytes in serum-containing complete media (RPMI 1640 (Life Technologies), 0.05 mg/
ml gentamicin (Life Technologies), 0.014 mg/ml hypoxanthine (Sigma), 38.4 mM HEPES (Sigma), 0.2% (w/v) sodium bicarbonate
(Sigma), D-glucose 0.2% (w/v) (Sigma), 3.4 mM sodium hydroxide (Sigma), 4.3% (v/v) heat-inactivated human serum (O+, Interstate
Blood bank), and 0.2% (w/v) AlbuMAX II (Life Technologies)). Parasites were cultured at 37oC under low-oxygen conditions (3%O2,
5% CO2, 92% N2) and parasitemias were maintained between 0.5% and 3% in cultures with 5% hematocrit. Ring-stage parasites
underwent three rounds of synchronization with 5% (w/v) D-Sorbitol (Sigma), on days -8, -6 and -4 relative to the day of initiating
gametocyte production. Trophozoite-stage parasites were shaken overnight at 37C until day -1. On day -2 only 50% of the media
was exchanged to provide additional stress to cultures, whose parasitemias had typically attained 7-10%. Complete media ex-
change was performed daily from day -1 onwards. Stage V gametocytes were treated with 50 mM N-acetyl glucosamine (Sigma)
on days 0-9. Gametocytes were then diluted to 0.7% gametocytemia and 1.25% hematocrit in serum-free screening medium
(RPMI 1640, 0.05 mg/ml gentamicin, 0.014 mg/ml hypoxanthine, 38.4 mM HEPES, 0.2% (w/v) sodium bicarbonate, 0.2% (w/v)
D-glucose, 3.4 mM sodium hydroxide, and 0.4% (w/v) AlbuMAX II). Using a MultiFlo dispenser, 40 ml of culture was dispensed
into 384-well plates pre-loaded with 50 nL of test or control compounds per well. Plates were then incubated at 37C for 72 h under
low O2 conditions. Cells were stained by adding 10 mL of 2.5 mMMitoTracker Red CMXRos and 0.13% saponin solution in screening
media to each well, followed by incubation for 120 min at room temperature in the dark. Plates were imaged using a high-content
imaging system (Operetta, PerkinElmer) and Harmony software used for image analysis. The second assay assessed gametocyte
susceptibility using a luciferase-based assay with 3D7elo1-pfs16-CBG99 transgenic parasites (Cevenini et al., 2014). Synchronized
N-acetylglucosamine (NAG)-treated early and late stage gametocytes (day 4 and 11 of gametocyte development, respectively) were
diluted to 2%hematocrit and exposed to eight serially diluted concentrations ofMMV030084 for 48 h in 96-well plates (final volume of
100 ml/well). Cell viability was then evaluated by adding a non-lysing formulation of 0.5 mM D-Luciferin substrate and measuring
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luciferase activity for 0.5 s on a Varioskan Flash Multimode Reader (Thermo Scientific). The percent of viability was calculated as a
function of drug concentration and IC50 values were derived by non-linear regression analysis and curve fitting (using GraphPad
Prism 6.0).
Dual Gamete Formation Assay
Pf NF54 gametocytes were generated as reported elsewhere (Delves et al., 2016). Briefly, static cultures of unsynchronized asexual
parasites were continuously maintained as above. Parasites were cultured at 1% ring-stage parasitemias and 4% (v/v) hematocrit
prior to the induction of gametocytes. To prepare gametocytes, 75%of themedia was replaced daily for 14 subsequent days without
adding fresh RBCs. During this process the temperature was kept strictly constant, as the rate of exflagellation is highly temperature-
dependent. Between days 1 and 4 after culture induction, the asexual parasitemias increased rapidly to a peak. By day 7, as the
asexual population waned, early-stage gametocytes became observable. By day 8, gametocyte maturation had progressed, and
by day 14 morphologically distinguishable, mature stage V male and female gametocytes were present. A ten-point serial dilution
of MMV030084 was prepared in DMSO and added to 100 ml culture medium in 1.5 ml tubes in a heater block at 37C. Control re-
actions contained DMSO or 20 mM methylene blue (as negative and positive controls, respectively). Gametocyte cultures were
diluted in culture medium to give 50 million cells/ml and then 100 ml was added to each 1.5 ml assay tube to give a final assay volume
of 200 ml and 25 million cells/ml. Tubes were briefly gassed with 3% (vol/vol) O2/5% CO2/92% N2, sealed and returned to a 37
C
incubator for 24 h. For the carry-over protocol, gametogenesis was induced in the presence of the drug. For the wash-out protocol,
gametogenesis was carried out only after cells had been washed three times to remove drug. Both the carry-over protocol tubes and
the wash-out tubes were then treated identically. Cells were concentrated by removing 100 ml of supernatant and were then resus-
pended in the remaining 100 ml that was quickly transferred to wells of a flat-bottomed 96 well plate containing a 1:100 dilution of a
Cy3-conjugated anti-Pfs25 antibody (Ruecker et al., 2014) in 10 ml ookinete medium to induce gametogenesis. The plate was then
transferred to an automated wide-field microscope. Twenty min after induction, exflagellation centers were imaged with bright-field
illumination using a 4x objective capturing 20 frames over 2 s. After imaging, the plate was incubated at 18C for a further 24 h to allow
female gametes to maximally express Pfs25, followed by fluorescence microscopy imaging using a 103 objective. Both time lapse
images of exflagellation and fluorescence images of female gametes were automatically quantified using custom scripts in ICY Bio-
Image Analysis (Delves et al., 2016). Inhibition was evaluated with respect to positive and negative controls (producing 100% or 0%
inhibition, respectively).
Metabolomics
Metabolomics experiments were performed as described elsewhere (Murithi et al., 2019). Briefly, sorbitol-synchronized trophozoites
were purified byMACS columns and either exposed to 103 the IC50 ofMMV030084 for 3 h or allowed to develop to the schizont stage
that was then exposed to 103 the MMV030084 IC50 for 3 h. Following several washes, metabolites were extracted by 90%methanol
containing 0.5 mM 13C15N-labelled aspartate as an internal standard. Nitrogen-dried samples were stored at -80C. Samples were
resuspended in high-performance liquid chromatography (HPLC) grade water that contained 1 mM chlorpropamide as an internal
standard. They were then analyzed by ultra-high-performance liquid chromatography mass spectrometry UHPLC-MS (Allman
et al., 2016). Data analysis was performed using the el-MAVEN software and the Metaboanalyst package in R Studio (Murithi
et al., 2019).
Phosphoproteomics
Sorbitol-synchronized Dd2-B2 wild-type and ed. Dd2-B2 TKL3KO schizonts were exposed to 1200 nM (33 the Dd2-B2 wild-type
IC50) of MMV030084 or control conditions for 3 h. Red blood cells were lysed by 0.1% saponin in washing buffer (20 mM b-glycer-
ophosphate, 1 tablet of cOmplete protease inhibitor cocktail (Roche), and 1 tablet of PhosSTOP phosphatase inhibitor (Roche) per
10ml PBS). Parasites were subsequently washed three times in washing buffer. Parasite pellets were stored at -80Cuntil all samples
from two independently repeated exposure experiments were collected. Proteins were extracted from schizont pellets by sonication
and lysis in Tris-EDTA buffer (10mMTris-HCl, 5 mMEDTA, 20mMß-glycerolphosphate; pH 7.4, 1%NP-40, 2%CHAPS) followed by
reduction of disulfide bonds and alkylation. Samples were digested with trypsin at a ratio of 1:15 (w/w) trypsin and proteins concen-
trated using S-trap columns (ProtiFi) for 1 h at 47C. For tandem mass tag (TMT) labelling, digested samples were incubated with
TMTsixplex reagents (Thermo Scientific). All labeled samples were pooled together, loaded onto an anion-exchange column, and
fractionated on an AKTA purifier (GE Healthcare). The fractions were concentrated and phosphopeptides were enriched using tita-
nium dioxide (TiO2) and immobilized metal affinity chromatography (IMAC). LC-MS/MSwas carried out using an Orbitrap Fusion with
a RSLCnano System (Thermo Scientific). The raw data from the LC-MS/MS acquisition was processed using Proteome Discoverer
(Thermo Scientific) and Mascot (Matrix Science) to search each file against the UniProtKB-Swissprot database with variable mod-
ifications set for oxidation (M) and phosphorylation (S/T/Y). Data were further processed in Scaffold Q+S (Proteome Software) and
then exported toMicrosoft Excel to calculate the difference (fold change) in themean log2 normalized intensities between control and
MMV030084-treated parasites for each peptide. We conducted a consensus motif analysis of the modified sequences for all the
significantly upregulated/downregulated peptides in order to identify phosphoproteins that were putative PfPKG substrates.
We also analyzed the peptide sequences for patterns that conformed to the previously established PfPKG consensus motif
K/RR/KxpS/pT and the PfPKA consensus motif K/RxxpS/pT (Francis et al., 2010).
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Chemoproteomics
Human extracts were prepared as described (Bantscheff et al., 2011). Briefly, frozen cell pellets were homogenized in lysis buffer
(50 mM Tris-HCl, 0.8% Igepal-CA630, 5% glycerol, 150 mM NaCl, 1.5 mMMgCl2, 25 mM sodium fluoride, 1 mM sodium vanadate,
1mMDTT, pH 7.5). One cOmplete EDTA-free protease inhibitor tablet (Roche) was added per 25ml. Sampleswere dispersed using a
Dounce homogenizer, rotated for 30 min at 4C, and centrifuged at 20,000g for 10 min at 4C. Supernatants were then recentrifuged
at 145,000g for 1 h at 4C. Protein concentrations were determined using a Bradford assay (BioRad). Aliquots were snap frozen in
liquid nitrogen and stored at 80C.
Pf protein extracts were prepared as described elsewhere (Paquet et al., 2017). Parasite cultures at the trophozoite stage were
harvested, washed twice in RPMI 1640 medium (Gibco), and lysed by the addition of saponin to a final concentration of 0.1% for
5 min at room temperature. Free parasites were sedimented by centrifugation (3500 rpm for 10 min), washed three times with phos-
phate-buffered saline, and stored at 80C. Parasites were resuspended in cell lysis buffer (50 mM tris-HCl (pH 7.5), 5% glycerol,
1.5 mM MgCl2, 1.5 mM NaCl, 1 mM Na3PO4, 25 mM sodium fluoride, 0.8% NP-40, EDTA-free protease inhibitor cocktail tablets
(Roche Diagnostics), and 1 mM DTT) and disrupted by sonication (Sonics Vibra-Cell) using two 30-s cycles on ice at half-amplitude.
After centrifugation (140,000g for 1 h at 4C), soluble proteins were recovered from the supernatants, and protein concentrations of
each sample were estimated using the Lowry-based DC assay (Bio-Rad). Samples were stored at 80C until use.
Kinobeads were prepared by immobilizing Bis-(III) indolyl-maleimide, purvalanol B, staurosporine and CZC8004, and the analogs
of PD173955, sunitinib and vandetanib on NHS-activated Sepharose 4 beads (Amersham) (Bantscheff et al., 2007). MMV030084 or
TCMDC-141154 were attached at a concentration of 1 mM to a NHS-activated Sepharose matrix via their primary amine moiety
(Bantscheff et al., 2007). The chemoproteomic affinity-capturing experiments were performed as previously described (Bantscheff
et al., 2011). Briefly, beadswerewashed and equilibrated in lysis buffer (50mMTris-HCl, pH 7.4, 0.4% Igepal-CA630, 1.5mMMgCl2,
5 % Glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na3VO4, 1 mM DTT, and one cOmplete EDTA-free protease inhibitor tablet (Roche)
per 25 mL). The beads were incubated at 4C for 1 h with either 0.1 ml (0.3 mg) Pf blood stage extract or 0.5 mL (2.5 mg) human cell/
tissue protein extract (amixture of HEK-293, K-562, HepG2 , and placental cells), whichwas pre-incubatedwith compound or DMSO
(vehicle control). 10 samples were measured in parallel (TMT 10-plex (Werner et al., 2014)) to generate values for the affinity of the
beads to the bound proteins (‘‘depletion’’ values, 4 samples) and to generate IC50 values (6 samples) in a single experiment. Apparent
dissociation constants were determined after accounting for protein depletion by the beads (Bantscheff et al., 2011). Beads were
transferred to Filter plates (Durapore PVDFmembrane,MerckMillipore), washedwith lysis buffer, and eluted with SDS sample buffer.
Proteins were digested according to a modified single pot solid-phase sample preparation (SP3) protocol (Hughes et al., 2014).
Peptides were labeled with isobaric mass tags (Thermo Fisher Scientific, Waltham, MA) using 10-plex TMT reagents, enabling rela-
tive quantification of 10 conditions in a single experiment (Werner et al., 2014). The labeling reactions and LC-MS/MSmeasurements
using Q Exactive Orbitrap or Orbitrap Fusion Lumos mass spectrometers (Thermo Fisher Scientific) were performed as described
elsewhere (Sridharan et al., 2019). Mascot 2.4 (Matrix Science, Boston, MA) was used for protein identification by using a 10 parts
per million mass tolerance for peptide precursors and 20 mD (HCD) mass tolerance for fragment ions. To create the fasta file for
mascot searching, all proteins corresponding to the taxonomy ‘Plasmodium falciparum (isolate 3D7)’ were downloaded fromUniprot
(release 20170621) and supplemented with common contaminant protein sequences of bovine serum albumin, porcine trypsin and
mouse, rat, sheep and dog keratins. To assess the false discovery rate (FDR), ‘‘decoy’’ proteins (reverse of all protein sequences)
were created and added to the database, resulting in a database containing a total of 14266 protein sequences, with 50% forward
and 50% reverse. For peptide and protein identification of human proteins see (Sridharan et al., 2019). Unless stated otherwise, we
accepted protein identifications as follows: (i) For single-spectrum to sequence assignments, we required this assignment to be the
best match and a minimum Mascot score of 31 and a 103 difference of this assignment over the next best assignment. Based on
these criteria, the decoy search results indicated <1% false discovery rate (FDR). (ii) For multiple spectrum to sequence assignments
and using the same parameters, the decoy search results indicated <0.1% FDR. Quantified proteins were required to contain at least
2 unique peptide matches. FDR for quantified proteins was <0.1%. Raw data tables for the chemoproteomics experiments can be
found in Table S1 (E1-3).
Generation of Constructs and Parasite Transfections for cKD Lines
To study the interaction between the compounds and PKG (PF3D7_1436600), AAT (PF3D7_1231400), CDPK1 (PF3D7_0217500),
TKL3 (PF3D7_1349300), PP1 (PF3D7_1414400), and URP (PF3D7_0808300), cKD lines were generated by fusing the transcripts
with RNA aptamers for translation regulation with the TetR/DOZI system (Ganesan et al., 2016). The right homology regions (RHR)
of each target gene were amplified by PCR, using the primers listed in Table S1 (A), and along with the left homology regions
(LHR) were fused to the re-codonized 3’-end region of the gene. Single guide RNA fragments were synthesized using the BioXP
3200 System (SGI-DNA; Table S1 (A)) and were cloned into the pSN054 vector (Nasamu et al., 2019) to install the C-terminal epitope
tags V5 and 2x-hemagglutinin (HA) followed by a 10x RNA aptamer array and the TetR-DOZI expression cassette. This cassette also
contained Blasticidin S-deaminase for selection in the parasites and the reporter gene Renilla luciferase (RLuc). The 3’-end of each
target was re-codonized to avoid further modifications of the edited locus in the parasite via removal of the PAM site. Donor vector
generation was carried out via Gibson assembly, and the final construct sequence was confirmed by restriction digests and Sanger
sequencing.
Transfection into parasites was carried out by preloading erythrocytes with linearized vectors as described previously (Deitsch
et al., 2001). Briefly, 50 mg of purified plasmid DNA was mixed with human RBC and subjected to 8 square wave electroporation
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pulses of 365 V for 1 ms each, separated by 0.1 s in a 0.2 cm cuvette. The plasmid DNA preloaded cells were inoculated with NF54
parasites expressing Cas9 and T7 RNA polymerase, maintained in 500 nM anhydrotetracycline (aTc, Sigma-Aldrich 37919), and drug
selection with 2.5 mg/mL of Blasticidin (RPI Corp B12150-0.1) was initiated four days after transfection. Emergence of transfectants
was monitored via Giemsa smears and RLuc measurements.
Verification of Conditional Knockdown (cKD) Strategy
Immunoblotting was carried out to confirm the regulation of target protein expression by the TetR-DOZI-aptamer system. Parasites
were cultured with (50 -nM) or without aTc for 72 h, and protein extracts from saponinlysed cells were mixed with protein loading
buffer, containing sodium dodecyl sulfate (SDS) and dithiothreitol (DTT), and loaded onto Mini-PROTEAN TGX Precast Gels
(4-15% gradient) in Tris-glycine buffer. Polyacrylamide gel electrophoresis separated proteins were transferred to a polyvinylidene
fluoride membrane using a Mini Trans-Blot Electrophoretic Transfer Cell system according to the manufacturer’s instructions and
blocked with 100 mg/mL skim milk in 13TBS/0.1% Tween. Membrane-bound proteins were probed with mouse anti-HA (1:3000;
Sigma, H3663) and rabbit anti-GAPDH (1:5000; Abcam, AB9485) primary antibodies, and anti-mouse (1:5000; Thermo Fisher Scien-
tific, 62-6520) and anti-rabbit (1:5000; Cell Signaling, 7074S) horseradish peroxidase (HRP)-conjugated secondary antibodies.
Following incubation in SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific, PI34080), protein blots
were imaged and analyzed using the ChemiDoc MP System and Image Lab 5.2.0 (Bio-Rad). The theoretical molecular weights
of the fusion proteins are 60.8, 101.8, 39, and 31.6 kDa for CDPK1, PKG, PP1, and the putative ubiquitin regulatory protein (URP),
respectively. Because no band was detected from AAT and TKL3 lysates following multiple experiments in both control and cKD
experiments, diagnostic PCRs using the primers listed in Table S1 (J) were employed to verify that the machinery for cKD was
in place.
Growth Assays Using cKD Lines
Parasite proliferation rates were assessed in the presence and absence of aTc, using luminescence as a readout of growth. Synchro-
nous ring-stage parasites were set up in triplicate in 96-well U-bottom BD Falcon plates and cultured in the presence (50 nM) and
absence of aTc. Expansion was measured at 0 and 72 h by quantifying luminescence using the Renilla-Glo(R) Luciferase Assay Sys-
tem (Promega E2750) and the GloMax Discover Multimode Microplate Reader (Promega). Parasite growth was determined from
normalized RLuc values, with samples treated with 200 nM chloroquine (a lethal concentration) included as no-growth controls.
Results were processed and visualized using Prism 8 (GraphPad Software). Experiments were performed on two independent oc-
casions and statistical significance was assessed using an unpaired t test.
Compound Susceptibility Assays Using cKD Lines
Stock solutions of MMV030084, MMV030734, and TMDC-140549 were dispensed into 96-well U-bottom BD Falcon plates and
serially diluted in complete medium to yield final concentrations ranging from 0.8-200 nM for MMV030084 and MMV030734 and
2.3-600 nM for TMDC-140549. Synchronized ring-stage cKD parasites in varying aTc concentrations (high = 50 nM, intermediate =
1.5 nM, low = 1 nM, and no aTc) were distributed into the drug plate. No-drug treatment and treatment with a lethal dose of chloro-
quine (200 nM) served as reference controls. Growth inhibition at the different concentrations was analyzed after 72 h using the lucif-
erase assay described above, and EC50 values were obtained from dose-response curves using Prism 8 (GraphPad Software).
PfPKG Docking Studies
The PfPKG structure was downloaded from the Protein Data Bank (PDB 5DYK). All calculations were performed using the Schro-
dinger molecular modeling suite (version 2018-2). This structure was analyzed using the Protein Preparation Wizard where force field
atom types and bond orders were assigned, missing atoms including hydrogens were added, tautomer/ionization states were as-
signed, residues were flipped to optimize the hydrogen bond network, and a constrained energy minimization was performed (Sastry
et al., 2013). The Receptor Grid Generator tool was employed to create a glide grid of 30 x 30 x 30 A˚3 around the predicted drug-
binding site. The compounds for docking were imported into Maestro as MDL SD files and prepared using the LigPrep tool at pH
7. Compounds were docked into the PfPKG glide grid usingGlideDock_XP (extra precision) with a van derWaals radii of ligand atoms
scaling factor of 0.80 and a partial charge cutoff for polarity of 0.15, followed by post-docking minimization (Friesner et al., 2004).
Poses and H-bonding interactions were displayed using the XP Visualizer.
Recombinant PfPKG Inhibition Assay
Full length PfPKG (PF3D7_1436600) was expressed in Escherichia coli as previously described (Baker et al., 2017). The N-terminal
His-tagged recombinant PfPKG protein was purified using HisTrap HP columns (GE Healthcare), followed by anion exchange and
size exclusion chromatography (HiLoad 16/600 Superdex 200 pg column, GEHealthcare). Final buffer composition of purified protein
was 50mM Tris-HCL pH 8.0, 150 mM NaCl, 10 mM b-mercaptoethanol, and 10% glycerol.
Kinase inhibition assayswere preformed based on previously describedmethods (Baker et al., 2017; Penzo et al., 2019), using ADP
formation as a measure of kinase activity. Briefly, 3-fold serial dilutions of MMV030084 were prepared in assay buffer (25 mMHEPES
pH 7.4, 0.01 % (w/v) BSA, 0.01 % (v/v) Triton-X 100, 20 mM MgCl2, 2 mM DTT, 10 mM cGMP). The final kinase reaction contained
1 nM purified PfPKG protein, 10 mMATP (~½ the Km of the enzyme), 20 mMpeptide substrate GRTGRRNSI-NH2 (Sigma-Aldrich, Cat
no. SCP0212), 1 % (v/v) DMSO and 1 mM – 0.15 nM inhibitor in assay buffer. Reactions were initiated by the addition of PfPKG and
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incubated for 30 minutes at 22C (resulting in <10% ATP conversion). ADP formation was measured using the ADP-Glo Kinase Kit
(Promega) according to manufacturer’s instructions. Briefly, 4 ml ADP-Glo Reagent was added to 4 ml kinase reaction in white 384
shallow-well plates (Nunc, Cat no. 264706) and incubated for 40 minutes at 22C to deplete the remaining ATP. 8 ml of Kinase Detec-
tion Reagent was then added and the reaction was incubated for a further 30 minutes at 22C. Luminescent signal was measured
using the EnSpire Multimode Plate Reader (PerkinElmer). Data were normalized based on the DMSO controls (no inhibitor, 100%
activity) and the 100% inhibition controls (1mM PfPKG inhibitor ML10 (Baker et al., 2017), LifeArc). The 100% inhibition controls
gave comparable readings to the negative controls (no enzyme). Reactions were carried out in duplicate and IC50 values were calcu-
lated based on the average of three independent experiments using GraphPad Prism (log(inhibitor) vs. normalized response – Var-
iable slope).
Selections for MMV030084 Resistance
Selections were initiated by exposing two independent flasks each containing 109 wild-type Dd2-B2 parasites to 450 nM of
MMV030084, i.e. 33 the 72 h ABS IC50. Medium containingMMV030084was refreshed daily until sensitive parasites were effectively
cleared, after which the medium was refreshed every other day and the culture volume was reduced gradually (as described else-
where (Istvan et al., 2019)). The resultingMMV030084-resistant parasites were cloned by limiting dilution (Baker et al., 2017) to obtain
genetically homogenous cultures for further phenotyping andwhole-genome sequencing. A second round of selections using the ed.
Dd2-B2 TKL3KO line included continuous exposure selections, as described above, and a pulsing selection in which parasites were
exposed to low drug concentrations (starting at 525 nM MMV030084) for shorter intervals and allowed to recover before being
exposed to gradually higher drug concentrations (up to 875 nM over the course of 67 days). Drug susceptibility of resistant lines
was assessed using a 72 h ABS assay as described above, and a Mann Whitney U test was applied to assess statistically significant
differences.
Whole-Genome Sequencing
DNA was extracted using the QiAmp DNA Blood Mini kit (Qiagen) and subjected to whole-genome sequencing using the Illumina
TruSeq DNA PCR-Free library preparation protocol and a MiSeq (Illumina) sequencing platform. Briefly, 2 mg of genomic DNA
were sheared to 550 bp size, end-repaired, adenylated on 3’ ends and ligated with adaptors. The samples were pooled and
sequenced on an Illumina MiSeq flow cell to obtain 300 bp paired end reads. The sequence data was aligned to the Pf parental
genome (PlasmoDB version 36) using BWA (Burrow-Wheeler Alignment). Reads that did not map to the reference genome and
PCR duplicates were removed using Samtools and Picard. The reads were realigned around indels using GATK RealignerTarget-
Creator and base quality scores were recalibrated using GATK Table-Recalibration. GATK HaplotypeCaller (version 3.8) (Min
Base quality scoreR 17) was used to identify of all possible variants in clones which were filtered based on quality scores (variant
quality as function of depth QD > 1.5, mapping quality > 40), read depth (depth of read > 5) to obtain high-quality single nucleotide
polymorphisms that were annotated using snpEFF. The list of variants from resistant clones were compared against the Dd2-B2
parental clone to obtain homozygous single nucleotide polymorphisms present exclusively in the resistant clones. Integrated
Genome Viewer was used to confirm polymorphisms present in resistant clones.
CRISPR/Cas9 Editing of TKL3
A CRISPR/Cas9 targeted gene editing strategy using an all-in-one plasmid approach was applied to introduce T1268R, I1250M and
T1268R+I1250M in wild-type Dd2-B2 parasites or to produce a TKL3 KO line by inserting a stop codon and frameshift at amino acid
position 1268. This all-in-one plasmid encoded (i) a codon-optimized Cas9 nuclease, (ii) a single guide RNA (5’-GATATTTGCTAGAA
GATTAAG-3’ or 5’-GTGTCTATCATCATGCGTTTC-3’) to complex the Cas9 nuclease to the target sequence, (iii) a tkl3 donor
sequence (nucleotides 3649–4019 of the PF3D7_1349300 coding sequence) that contained T1268R and/or I1250M, or T1268*
and 10 binding site mutations to prevent Cas9 cleavage of the edited locus through any of the two guides, and (iv) a human dhfr
cassette that mediates resistance to WR99210. Sorbitol-synchronized ring-stage cultures were transfected with two such plasmids
each containing a different guide RNA sequence to maximize the chance of successful editing. Transfections were performed with a
Gene Pulser II (Bio-Rad) at 0.31 kV and 910 mF at maximum capacitance. WR99210 (2.5 nM) was added to the culture medium 24 h
after electroporation to select for successfully transfected parasites and was maintained in the medium until edited parasites were
detected. Genetic editing was verified by PCR and Sanger sequencing and edited lines were subjected to limiting dilution cloning to
obtain genetically homogeneous parasite populations.
Expression, Purification and Kinase Assay of WT and Kinase Dead Recombinant PfTKL3 Kinase Domain
Recombinant proteins were expressed in E. coli as previously described (Abdi et al., 2010). Briefly, E. coli Rosetta2-pLysS cells (No-
vagen), transformed with expression plasmids pET28-PfTKL3-SAM(V54E)-KD expressing the wild-type or catalytically inactive ki-
nase domain of TKL3, were inoculated 1:500 into 500 ml 2YT culture medium with kanamycin/chloramphenicol (100 and 34 mg/
ml, respectively) at 37C, with agitation at 200 rpm, and cultured up to an OD600 of 0.5. The cultures were then cooled to 20C fol-
lowed by induction of protein expression with 0.5 mM IPTG and further incubation at 20C, 200 rpm for 16 h. Cultures were harvested
by centrifugation at 4000g, 4C for 10min. Bacterial pellets were washed once in 13PBS andwere stored at80C. Cell pellets were
resuspended in ice-cold Lysis Buffer (50 mM sodium phosphate, pH 8.0, 400 mM NaCl, 5 % (w/v) glycerol, 0.1 % (v/v) Triton X-100,
20 mM imidazole, 2 mM b-mercaptoethanol, 13 Roche protease inhibitor cocktail EDTA-free, 1 mg/ml lysozyme). Cells were
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disrupted by sonication. Protein was bound on a HisTrap HP column and eluted with a linear gradient of increasing imidazole con-
centrations. The peak fractions as determined by A280 trace were pooled together and further purified by size exclusion chromatog-
raphy on a S200 gel filtration column equilibrated in 25 mM Tris pH 7.5, 100 mM NaCl, 5 % (w/v) glycerol, 1 mM DTT. Protein was
pooled and concentrated. Final concentration was determined using a Bradford assay with a BSA protein standard.
Kinase assays containing 3 mg of recombinant kinase (WT or mutant) were performed in kinase assay buffer (25 mMHepes, pH 7.5,
2mMMnCl2, 10mM b-glycerophosphate, 10mMNaF, 25 mMATP (containing 5 mCi [g-
32P]-ATP-3000mCi/mmol (PerkinElmer)), 5 mg
substrate myelin basic protein (MBP) and ± 20 mM inhibitor) in a final reaction volume of 20 ml and incubated at 30C for 30 min. Re-
actions were stopped by the addition of 53 Laemmli sample buffer and heated to 98C for 5 min. Proteins were resolved by 4-12 %
SDS-PAGE and stained in Coomassie Brilliant Blue. Kinase activity was detected by phosphorimaging. Imaging was performed on a
Typhoon 5 Biomolecular imager (GE Healthcare Life Sciences).
QUANTIFICATION AND STATISTICAL ANALYSIS
All biochemical curves and statistical analyses were produced using Prism 8 (GraphPad Software). Details regarding statistical tests
are reported in the Figure Legends and Supplemental Information.
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